Our strategic focus on heart failure


Heart failure, a global health burden

We are investing in research for the future of the estimated 38 million people impacted by heart failure worldwide.

Heart failure is among the leading causes of death due to cardiovascular disease (CVD), and occurs when the heart is weakened and cannot pump enough blood to meet the body’s needs.

People with HF are likely to be diagnosed with significant cardiovascular (CV), renal and metabolic risk factors such as type-2 diabetes and chronic kidney disease (CKD). People with type-2 diabetes have 2-3 times greater risk of HF and are at an increased risk of having a heart attack or stroke than the population without type-2 diabetes, and approximately 50% of deaths in people with type-2 diabetes are caused by CVD.

Due to the interconnectivity of CV, renal and metabolic diseases, we are committed to taking an overarching cardio-renal-metabolic approach to researching and innovating medicines for patients with HF. 


CVD-REAL: Large-scale real-world evidence data

AstraZeneca is investigating the potential impact of SGLT-2 inhibitors on hospitalisation for HF and death in patients with type-2 diabetes 

CVD-REAL is the first large, multi-national real-world evidence study of its kind evaluating the risk of hospitalisation for HF and death from any cause in patients with type-2 diabetes receiving treatment with SGLT-2 inhibitors. 


What we're working on

We’re dedicated to investigating the science behind HF and how we can find benefits across the cardio-renal-metabolic disease area.



Other resources


References

1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015; 385 (9970): 812-824.

2. Kumarswamy R, Thum T. Non-coding RNAs in Cardiac Remodeling and Heart Failure. Circulation Research. 2013; 113:676-689.

3. American Heart Association. What is Heart Failure? http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/What-is-Heart-Failure_UCM_002044_Article.jsp#.WZOU-FF97IU. Accessed 15 August 2017.

4. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and metaanalysis. The British Journal of Diabetes & Vascular Disease. 2013;13(4):192-207.

5. Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14-21.

6. Martín-Timón I, Sevillano-Collantes C, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444-470.


Veeva ID: Z4-6504
Date of expiry: August 2018